We help our clients appreciate, understand, and arrive at informed decisions that capture value and thereby succeed. ![]() We identify and address appropriate opportunities, problems, and questions through practical experience, academic rigor, business acumen, and a passion for our work. MME’s value-based solutions provide our clients with unique guidance, insights, marketing strategies, and tactics. Medical Marketing Economics (MME) is a global leader in the development of value-based strategies and research for health care goods and services. As a recognized expert consultant since 2001, he has successfully completed engagements encompassing many product classes and therapeutic areas and markets, including chronic care, oncology, injectable, rare diseases, gene therapies, and other specialty products all centered on value and its interaction with pricing, payers, reimbursement, and marketing in general at both MME and predecessor organizations. Elements of Pharmaceutical/Biotech PricingĪs MME’s Global President & CEO, Jack provides critical global support for strategic marketing and pricing decisions to clients in the biotech and pharmaceutical industries. Martin is contributing to national policy research on opioids and health care financing and has recently lead an international effort to improve the conduct and reporting of CER observational research organized by three national associations: ISPOR, NPC, AMCP. Martin has over 90 peer-reviewed manuscripts published, which have been collectively cited over 4000 times, and his work has been funded by NIH, AHRQ, VA, and a variety of research foundations as well as partnerships with the pharmaceutical industry. He conducts policy analyses, and develops cost effectiveness models and has contributed to the understanding of the opioid epidemic. Martin’s research efforts have focused on conducting retrospective observational comparative effectiveness and economic analyses using large administrative data sets and national health surveys. Martin received his PharmD from the University of Illinois and earned his PhD in Pharmacy Care Administration from the University of Georgia. The Pharmaceutical Evaluation and Policy Division offers graduate and professional instruction and conducts research in pharmacoeconomics, patient reported outcomes, pharmaceutical economics, and large health claims data base analysis. Bradley Martin is currently professor and was the founding head of the Pharmaceutical Evaluation and Policy (PEP) Division at the University of Arkansas for Medical Sciences College of Pharmacy. University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USAĭr. Dr Jönsson is the author of 80+ original publications, reviews and book chapters. ![]() ![]() He is chairman of the board of the Swedish Institute of Health Economics and has served as advisor to the National Board of Health and Welfare for the development of national treatment guidelines in Sweden. Recently his research interests include value of innovation in health care with particular focus on digitalization of health care systems as well as neurodegenerative disorders. ![]() He is Associate Professor of Health Economics at Karolinska Institutet, Stockholm, where his research has focused on health technology assessment and economic evaluation in a range of disease areas including Alzheimer’s disease, depression and oncology. based consultancies in Health Economics and Outcomes Research. His background is in clinical medicine and Economics and he previously held positions at European and U.S. Dr Jönsson is Vice President, Medical Outcomes Research at H.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |